Jazz Pharmaceuticals

Jazz Pharmaceuticals

Verified
Identifying, developing and commercializing meaningful products that address unmet medical needs
Palo Alto United States (HQ)
Deals in the last 12 months undisclosed
Unicorns in portfolio: Celator Pharmaceuticals

Company information

Edit
Launch date
Employees
2,321 people
Ownership
Market cap
$9.0b
Net debt
$465m
Firm valuation
€8.0b (Public information from 2021)
Revenues, earnings & profits over time
USD20162017201820192020E2021E2022E
Revenues-1.6b1.9b2.2b2.3b2.5b2.7b
% growth--17 %14 %8 %8 %8 %
EBITDA-908m1.0b1.1b974m1.3b1.4b
% EBITDA margin-56 %55 %52 %42 %50 %51 %
Profit-488m447m523m342m677m813m
% profit margin-30 %24 %24 %15 %27 %30 %
EV / Revenue-5.7x4.6x4.4x4.0x3.5x2.9x
EV / EBITDA-10.2x8.4x8.4x9.7x6.9x5.7x
  • Edit
DateInvestorsAmountRound
N/A$7.1mSERIES A
$250mSERIES B
N/A$108mIPO
$7mPOST IPO EQUITY
N/A$120mPOST IPO DEBT
Total Funding€234m

Recent News about Jazz Pharmaceuticals

Edit
LocationEdit
United States, Palo Alto
Are you an employee or an investor of this company?
Add your profile